This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...

Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals ...

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Aug. 13, 2002 -- A study of vascular endothelial growth factor (VEGF) reported in the Aug. 15 issue of Cancer may help explain the biological basis for the link between social support and cancer ...

Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this ...

The literature presented in this review does not indicate a clinically relevant relationship between genetic variations in the VEGF system and the risk of CRC. Hence, these markers will probably not ...